Engflag

Trazimera

Quick links to important sections

Trazimera

Trazimera_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trazimera

Quick Facts

Property Description
Active ingredient Trastuzumab-qyyp (Monoclonal Antibody)
Form Lyophilized powder for concentrate for solution for infusion
Pharmacological class HER2/neu Receptor Antagonist
Common use (General) Targeted therapy for conditions involving HER2 overexpression
Origin Biological drug, Biosimilar (Recombinant DNA technology)

What Type of Medicine is Trazimera (Trastuzumab-qyyp)?

Trazimera is a prescription-only biological drug whose active component, Trastuzumab-qyyp, is clinically recognized as a biosimilar monoclonal antibody. This means Trazimera is a complex protein produced using highly specialized cell culture and recombinant DNA technology, fundamentally distinguishing it from chemically synthesized small-molecule drugs. The biosimilar designation indicates that Trazimera is highly similar to the reference product, Trastuzumab, with no clinically meaningful differences concerning purity, potency, and safety. Trazimera is supplied as a sterile, lyophilized powder in vials, which is reconstituted by a healthcare professional to form a solution for delivery via intravenous infusion.

Composition, Class, and General Purpose

The active ingredient, Trastuzumab-qyyp, is a humanized IgG1 monoclonal antibody that belongs to the pharmacological class of HER2/neu receptor antagonists. This classification indicates that the medicine is specifically designed to block a critical biological target in the body. The general purpose of Trazimera is to provide targeted therapy by interfering with the growth signals transmitted by the HER2 protein when that protein is overexpressed on cell surfaces. This biosimilar is indicated for conditions where the HER2 protein is highly active, representing a focused approach to inhibit cell proliferation. This binding action specifically helps to block the signals that drive uncontrolled cellular multiplication.

Regulatory References

  1. EMA EPAR: Trazimera (trastuzumab)

What side effects are possible with Trazimera?

Possible Side Effects and Safety Information

The safety profile of Trazimera is formally documented by regulatory authorities, classifying potential effects by frequency and the body system involved.

Documented Serious Adverse Reactions

Official labeling highlights several serious risks, often designated as Boxed Warnings, that require careful patient monitoring. These include Cardiomyopathy and other forms of cardiac dysfunction, which may manifest as clinical or fatal heart failure. Serious and sometimes fatal Pulmonary Toxicity, such as interstitial pneumonitis, is also documented. Additionally, severe and life-threatening Infusion Reactions (e.g., anaphylaxis) may occur, typically during or within 24 hours of administration.

Common Adverse Reactions and Organ Systems

Adverse reactions that are classified as most common (e.g., 10% incidence) across various indications include general symptoms such as fever, chills, and fatigue, along with headache, diarrhea, and nausea. Effects are grouped into System-Organ Classes, covering areas like Gastrointestinal Disorders (diarrhea, stomatitis), Infections and Infestations, Blood and Lymphatic System Disorders (neutropenia, anemia), and Nervous System Disorders.

Population-Specific and Exposure Constraints

Specific safety considerations apply to certain populations. Embryo-Fetal Toxicity is a known risk; therefore, females of reproductive potential must use effective contraception during treatment and for a documented period of 7 months following the last dose. The official label requires regular Left Ventricular Ejection Fraction (LVEF) monitoring before, during, and after treatment to manage the risk of cardiac dysfunction, especially when administered with or after anthracycline-containing chemotherapy.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Trazimera

Overdose scope
Documented overdose presentations: A symptom complex including fever, chills, dyspnea, hypotension, headache, and dizziness, typically occurring during or within 24 hours of administration (Source: FDA Prescribing Information).
Physiological systems affected (as stated in label): Cardiovascular (sub-clinical and clinical cardiac failure, decreased LVEF, arrhythmias) and Pulmonary (dyspnea, Acute Respiratory Distress Syndrome, interstitial pneumonitis) (Source: FDA Prescribing Information).
Dose-related or exposure-related factors (if applicable): Cardiac failure risk is highest when administered with anthracycline-containing chemotherapy (Source: FDA Prescribing Information). Exposure during pregnancy can result in oligohydramnios and neonatal death (Source: FDA Prescribing Information).
Population-specific overdose notes (if applicable): Patients with pre-existing symptomatic intrinsic lung disease are at risk of more severe pulmonary toxicity (Source: FDA Prescribing Information).
Emergency-response statements (as written in official documents): Interrupt the infusion for dyspnea (shortness of breath) or clinically significant hypotension. Monitor patients until symptoms completely resolve (Source: FDA Prescribing Information).
When immediate medical help is required (label-derived phrasing only): Immediate medical help is required for serious or fatal infusion reactions (e.g., anaphylaxis or angioedema) or severe manifestations of cardiac failure (Source: FDA Prescribing Information).

Overdose classifications (high-level)
Severity classification (as defined in official documents): Infusion reactions and pulmonary toxicity are classified as potentially serious and fatal. Cardiac effects can result in disabling cardiac failure or cardiac death (Source: FDA Prescribing Information).
Regulatory basis (EMA / FDA / etc.): No specific antidote is known for Trazimera (Source: General regulatory information).
Overdose-context constraints (as defined in official documents): Management relies on symptomatic and supportive treatment (Source: NIH/MedlinePlus). Permanent discontinuation is mandated for severe reactions like ARDS (Source: FDA Prescribing Information).

Resulting overdose structure

  • No specific antidote is known for overdose of Trazimera, confirming that treatment is based on supportive care.
  • The infusion must be interrupted immediately for the documented manifestations of dyspnea or clinically significant hypotension.
  • Severe or fatal outcomes, including anaphylaxis, Acute Respiratory Distress Syndrome, and cardiac death, mandate the permanent discontinuation of Trazimera.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile not by a single syndrome, but by a cluster of severe, dose-related toxicities, primarily affecting the cardiac and pulmonary systems, which necessitate strict adherence to specific interruption or discontinuation rules. Since there is no known specific antidote, the official guidance strictly mandates that medical help is sought immediately upon the manifestation of severe symptoms to allow for symptomatic and supportive treatment and required monitoring. The required help-seeking actions are explicitly tied to the onset of life-threatening signs that indicate the body's maximum tolerance has been exceeded.

Therapeutic Uses of Trazimera

What Trazimera Treats: Main Uses and Benefits

Trazimera is a targeted biological therapy commonly used for cancers that overexpress the HER2 protein, and is considered relevant for addressing the growth associated with this protein. The medicine is generally used in adults to help manage conditions such as HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. These clinical applications are based on the medicine's established use for specific indications.

This treatment is applicable across domains where additional symptomatic support is needed, primarily in two key clinical scenarios. For patients with metastatic disease, Trazimera is applied as a systemic treatment, which may assist with the management of disease advancement, generally supporting a potential long-term clinical benefit.

In the adjuvant setting for early-stage breast cancer, this therapy helps manage the risk of the cancer returning and may assist with maintaining functional stability. Its use is applied in contexts where additional support is needed to address the risk posed by potential microscopic disease.

Quick Fact: Relevant for HER2-Driven Malignancy

Domain of Use Primary Patient Benefit Clinical Scenario
Oncology Contributes to easing the overall symptom load Metastatic disease management
Risk Reduction May assist with risk management Adjuvant treatment post-surgery

Eligibility and Restrictions for Use

Who Can and Cannot Use Trazimera?

Eligibility for Trazimera is strictly determined by regulatory requirements, focusing on the patient's disease characteristics, age, and existing health conditions.

Required Eligibility Status

Treatment is formally allowed only for adults (18 years and older) whose tumors overexpress the HER2 protein, a condition confirmed by a specific diagnostic test.

Absolute Non-Eligibility

The medicine is contraindicated (must not be used) in patients who meet specific criteria outlined in official labeling:

  • Known Hypersensitivity: Individuals with a history of allergy to the active substance, trastuzumab, mouse proteins, or any component of the formulation.
  • Severe Respiratory Impairment: Patients experiencing severe difficulty breathing (dyspnoea) at rest due to their advanced malignancy, or those requiring supplementary oxygen therapy.

Conditional Use and Restrictions

Condition Regulatory Requirement
Cardiac Health Conditional use. Baseline cardiac function (LVEF) must be assessed. The medicine is generally excluded for patients with symptomatic congestive heart failure.
Pregnancy/Lactation Use not recommended/restricted. Due to the risk of fetal harm, females of reproductive potential must use effective contraception during treatment and for at least 7 months following the final dose. Breastfeeding is also not recommended during this period.
Age (Pediatric) Use not established. There is no relevant use established for the pediatric population (children and adolescents).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation on Trazimera (trastuzumab-qyyp) emphasizes the potential for pharmacodynamic risk and specific procedural restrictions.

The most critical documented interaction is with anthracyclines (such as doxorubicin or epirubicin). Co-administration with anthracycline-containing regimens is associated with the highest incidence and severity of cardiac dysfunction, confirming an additive toxicity risk. Due to the long estimated washout period of Trazimera, regulatory guidelines advise that anthracycline-based therapy should be avoided for up to seven months following the final dose of Trazimera to mitigate this risk.

Administration and Substitution Rules

Trazimera carries explicit restrictions regarding how it is used with other products:

  • Mixing Prohibition: It must not be mixed with any other intravenous drug in the same infusion container.
  • Substitution Ban: It is formally prohibited from being substituted for, or used interchangeably with, ado-trastuzumab emtansine.

Lack of Documented Metabolic Interactions

Regulatory data does not document significant metabolic interactions. The official pharmacokinetic findings indicate that Trazimera does not alter the plasma exposure of co-administered agents like paclitaxel or doxorubicin. Furthermore, no formal studies have been performed or documented on interactions involving cytochrome P450 enzymes, drug transporters, food, alcohol, or herbal products.

Mechanism of Action

Trazimera (trastuzumab) is a humanized monoclonal antibody that executes its pharmacodynamic effect through three primary mechanistic domains to modulate cellular signaling and survival processes. The drug targets the Human Epidermal Growth Factor Receptor 2 (HER2) protein, a transmembrane receptor.

Targeted Receptor Blockade

Trazimera binds with high affinity to the extracellular domain of HER2, acting as an antagonist to receptor dimerization and activation. This interaction directly interferes with the receptor's intrinsic signaling capacity, leading to the inhibition of cell proliferation pathways and altered cellular signal transduction.

Modulation of Intracellular Cascades

The physical blockade of HER2 suppresses the activation of critical downstream intracellular pathways. Specifically, Trazimera prevents the recruitment and phosphorylation necessary for the initiation of the PI3K/AKT and MAPK signaling cascades, modifying early molecular steps that regulate cell cycle progression.

Immune System Engagement

Beyond direct blockade, Trazimera induces a system-level physiological modulation by mediating an immune response. The antibody's Fc region recruits and activates immune effector cells, primarily Natural Killer (NK) cells, facilitating Antibody-Dependent Cellular Cytotoxicity (ADCC). This mechanism mediates lysis of cells expressing the HER2 protein.

Dosage and Administration Information

How Trazimera is Used: Official Administration Guidelines

Trazimera (trastuzumab-qyyp) is a prescription biological medicine administered exclusively via intravenous (IV) infusion. It is supplied as a lyophilized powder in vials (150 mg or 420 mg) and must be reconstituted and diluted by a healthcare professional prior to use. Administration as an IV push or bolus is prohibited.

Dosing and Scheduling Principles

Official dosing is calculated based on the patient's body weight (mg/kg). Two primary dosing schedules are used in clinical practice:

  • Weekly Regimen: This schedule begins with a 4 mg/kg loading dose, followed by a 2 mg/kg maintenance dose administered once every week.
  • Three-Weekly Regimen: This begins with an 8 mg/kg loading dose, followed by a 6 mg/kg maintenance dose administered once every three weeks.

In the adjuvant setting, treatment duration is generally defined as 52 weeks (one year). In the metastatic setting, therapy is typically continued until the observation of disease progression.

Procedural and Administration Conditions

  • Preparation: The calculated dose must be diluted into 250 mL of 0.9% Sodium Chloride Injection, USP. The medicine must not be diluted with 5% Dextrose solution or mixed with other drugs.
  • Infusion Time: The initial loading dose is administered slowly, typically over 90 minutes. Subsequent maintenance doses may be administered over 30 minutes, provided the initial infusion was well-tolerated.
  • Missed Doses: If a scheduled dose is missed by more than one week, a re-loading dose (the initial dose for that specific regimen) is required to re-establish the correct protocol. No routine dose adjustments are specified for older adults or organ impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Trazimera

The Evidence Basis: Biosimilarity and Extrapolation

Trazimera is categorized as a biosimilar medicine, meaning its regulatory approval is based on a comprehensive research package describing a high degree of similarity to the reference product, Trastuzumab. This evidence foundation includes in-depth analytical studies that examine the physical and chemical properties of the drug, as well as functional assays that examine characteristics of the drug in a lab setting.

The initial clinical evaluation involved pharmacokinetic (PK) studies which measured how the medicine moves through the body in both healthy volunteers and patient populations. These initial studies suggested that the absorption and elimination of Trazimera were similar to the reference product. Regulatory reviews described patterns consistent with no clinically meaningful differences between the biosimilar and the reference product.

Evidence for Use in HER2-Overexpressing Metastatic Breast Cancer

The structure of the clinical research for Trazimera focused primarily on Phase III comparative trials conducted in adult patients with previously untreated HER2-positive metastatic breast cancer. These studies were designed to establish clinical equivalence between the biosimilar and the reference product, rather than establishing absolute efficacy against a placebo, which was established by historical trials.

Researchers examined endpoints such as the Overall Response Rate (ORR), Progression-Free Survival (PFS), and Overall Survival (OS). Findings indicated that the biosimilar was observed to be within the prespecified range established for the reference product for the primary endpoint of ORR. The research contributes to the broader evidence landscape by describing patterns of similarity.

Evidence for Use in Early-Stage Breast Cancer (Adjuvant Setting)

The research supporting the use of Trazimera for early-stage breast cancer relies on a combination of studies, including those that evaluated Pathological Complete Response (pCR) in the neoadjuvant setting. However, regulatory approval for its use across all approved indications is supported by the principle of extrapolation. This regulatory principle allows the evidence of the reference product’s use to be applied to this setting, based on the established analytical and clinical similarity.

Evidence in Specific Patient Groups and Key Research Gaps

There is limited direct comparative evidence for the biosimilar in the gastric cancer indication, and its use here relies solely on the regulatory principle of extrapolation. A key research limitation is that the primary clinical trial focused on confirming similarity rather than establishing independent efficacy. Dedicated pharmacokinetic studies in the elderly or those with severe organ impairment have not been specifically carried out, though research is ongoing in broader patient groups.

Frequently Asked Questions (FAQ)

Common questions about Trazimera (FAQ)

Q: What is Trazimera?

A: Trazimera is a biosimilar drug to the reference product Herceptin (trastuzumab). It is a type of targeted therapy called a monoclonal antibody. The regulatory label indicates it is used to treat certain types of HER2-positive breast cancer, HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.

Q: How is Trazimera administered?

A: Trazimera is given as an infusion directly into a vein (intravenously) by a healthcare professional in a clinic or hospital setting. The infusion process typically takes a specific amount of time. It is not available as an oral medication.

Q: What are the most common side effects of Trazimera?

A: The prescribing information lists common side effects, which may include chills, fever, nausea, pain, headache, and trouble sleeping (insomnia). Patients should discuss all potential side effects and concerns with their healthcare provider.

Q: Can Trazimera cause heart problems?

A: The regulatory information includes a Boxed Warning regarding the risk of cardiotoxicity, or damage to the heart muscle, which can lead to heart failure. Due to this risk, the patient's heart function is typically monitored by the healthcare team before and during treatment.

How should Trazimera be stored and disposed of?

How to Store and Dispose of Trazimera

Storage Requirements

Unopened Trazimera vials must be kept in the original carton to protect the product from light and stored in a refrigerator between 2 C to 8 C (36 F to 46 F). Do not freeze the vial or the reconstituted solution. A vial that has been stored at room temperature (up to 30 C) for its specified period must not be returned to the refrigerator.

Product State Storage Temperature Stability/Discard Time
Unopened Vial 2 C to 8 C Until Expiration Date
Multiple-Dose Vial (with preservative) 2 C to 8 C Discard after 28 days
Single-Dose Vial (without preservative) 2 C to 8 C Discard after 24 hours

Disposal Instructions

Unused or expired Trazimera must be discarded after the official stability or expiration date has passed. Any unused portion of the product should be disposed of in accordance with healthcare provider or pharmacy instructions regarding pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Trazimera found in:

A-Z Index: